Tmub1 Antibody

What is TMUB1 and what cellular functions does it perform?

TMUB1 (Transmembrane and ubiquitin-like domain-containing protein 1) is a multifunctional protein involved in several important cellular processes. It participates in sterol-regulated ubiquitination and degradation of HMG-CoA reductase HMGCR and regulates AMPA-selective glutamate receptor GRIA2 recycling to the cell surface. Additionally, TMUB1 functions as a negative regulator of hepatocyte growth during regeneration and contributes to translation regulation during cell-cycle progression. Recent research has revealed its significant role in modulating PD-L1 post-translational modifications in tumor cells, with important implications for cancer immunotherapy . TMUB1 is also known by alternative names including DULP, HOPS, SB144, and UNQ763/PRO1555, reflecting its identification through different research contexts .

What types of TMUB1 antibodies are currently available for research applications?

Several validated TMUB1 antibodies are available for research applications, with varying specifications suited to different experimental needs:

These antibodies have been rigorously tested and cited in peer-reviewed publications, making them reliable tools for TMUB1 research .

What criteria should guide the selection of an appropriate TMUB1 antibody for specific research applications?

When selecting a TMUB1 antibody, researchers should consider several critical factors to ensure optimal experimental outcomes:

• Experimental technique compatibility: Choose antibodies validated for your specific application (WB, ICC/IF, IHC-P, Flow Cytometry) .

• Epitope recognition: Consider which domain of TMUB1 you need to detect, especially if studying specific interactions or modifications.

• Validation stringency: Prioritize antibodies validated in knockout models, as these provide the strongest evidence of specificity .

• Sample type compatibility: Ensure the antibody has been validated with your sample type (tissue sections, cell lysates, etc.) .

• Buffer formulation: For sensitive applications, consider BSA and azide-free formulations that won't interfere with downstream applications .

The selection should be guided by the specific research question, as different applications may require different antibody characteristics to yield reliable results.

What are the optimal protocols for using TMUB1 antibodies in Western blot applications?

For optimal Western blot results with TMUB1 antibodies, researchers should follow these methodological guidelines:

• Sample preparation:

  • Load approximately 20 μg of total protein per lane

  • Include both positive controls (HepG2, Human Cerebellum tissue lysate) and negative controls (TMUB1 knockout cell lysates)

• Electrophoresis and transfer:

  • Use reducing conditions for optimal results

  • Expected molecular weight: 26 kDa (predicted), typically observed at 27 kDa

• Antibody incubation:

  • Primary antibody dilutions:

    • Rabbit Recombinant Monoclonal [EPR14066]: 1:10,000

    • Rabbit Polyclonal (16638-1-AP): 1:500-1:1,000

  • Incubate overnight at 4°C for optimal results

• Detection:

  • Use fluorescent or HRP-conjugated anti-rabbit secondary antibodies

  • Include a loading control (e.g., GAPDH at 37 kDa)

This protocol has been validated to produce a specific band at approximately 27 kDa in human samples, with complete signal loss in TMUB1 knockout controls .

How should researchers optimize immunohistochemistry protocols for TMUB1 detection in tissue samples?

Successful immunohistochemical detection of TMUB1 requires careful optimization:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) sections

  • Section thickness of 4-6 μm is recommended

• Antigen retrieval (critical step):

  • Perform heat-mediated antigen retrieval with EDTA buffer (pH 9)

  • This step is essential for unmasking epitopes and ensuring specific staining

• Antibody application:

  • For monoclonal antibody [EPR14066]: use at 1:100 dilution

  • Incubate overnight at 4°C in a humidified chamber

  • Human liver tissue serves as a positive control

• Detection system:

  • Use appropriate HRP-conjugated secondary antibodies

  • Develop with DAB substrate and counterstain as needed

The successful implementation of this protocol yields specific staining pattern of TMUB1 in human tissue samples, with appropriate subcellular localization patterns .

What methodological approaches are recommended for studying TMUB1's role in PD-L1 regulation and cancer immunotherapy?

To investigate TMUB1's role in PD-L1 regulation, researchers should employ these methodological approaches:

• Protein interaction studies:

  • Co-immunoprecipitation assays to confirm direct TMUB1-PD-L1 interaction

  • Competitive binding experiments with HUWE1 (E3 ubiquitin ligase) to demonstrate the competition mechanism

• Post-translational modification analysis:

  • Ubiquitination assays focusing on K281 residue of PD-L1

  • N-glycosylation assessment using glycosidase treatments

  • Pulse-chase experiments to measure PD-L1 stability

• Functional immune assays:

  • Membrane fractionation to quantify cell surface PD-L1 expression

  • T cell killing assays using co-culture systems with TMUB1-modified cancer cells

  • Measurement of IFN-γ and TNF-α production by activated T cells

• In vivo tumor immunity studies:

  • Xenograft models with TMUB1 knockdown/overexpression

  • Evaluation of tumor growth, CD8+ T cell infiltration, and response to immunotherapy

These methodological approaches have revealed that TMUB1 enhances PD-L1 glycosylation and stability by recruiting STT3A, thereby promoting tumor immune evasion, findings with significant implications for cancer immunotherapy development .

What are common challenges in TMUB1 antibody experiments and how can they be addressed?

Researchers working with TMUB1 antibodies may encounter several technical challenges that require systematic troubleshooting:

• Non-specific binding in Western blots:

  • Challenge: Additional bands beyond the expected 27 kDa

  • Solution: Optimize blocking (3-5% BSA or non-fat milk), increase antibody dilution, and use TMUB1 knockout controls for definitive band identification

• Weak or variable signal intensity:

  • Challenge: Inconsistent detection across experiments

  • Solution: Ensure consistent protein loading, verify sample integrity, optimize antigen retrieval for IHC/ICC, and confirm antibody storage conditions

• Discrepancies between different detection methods:

  • Challenge: Different results between WB, IHC, and flow cytometry

  • Solution: Consider native vs. denatured protein conformations, epitope accessibility differences, and use multiple antibodies targeting different epitopes

• Background issues in immunofluorescence:

  • Challenge: High background obscuring specific signal

  • Solution: Implement additional washing steps, pre-absorb secondary antibodies, and optimize fixation conditions

Successful resolution of these challenges requires systematic optimization and inclusion of appropriate controls, particularly TMUB1 knockout samples which provide definitive validation of antibody specificity .

How can researchers assess and validate the specificity of TMUB1 antibody detection?

Rigorous validation of TMUB1 antibody specificity is essential for generating reliable data:

• Genetic validation approaches:

  • TMUB1 knockout cell lines: The most stringent validation shows complete signal loss in knockout samples (e.g., TMUB1 knockout HeLa cells)

  • siRNA/shRNA knockdown: Signal reduction correlating with knockdown efficiency provides strong evidence of specificity

• Biochemical validation:

  • Multiple antibody comparison: Consistent results with antibodies targeting different epitopes

  • Immunoprecipitation followed by mass spectrometry: Confirms identity of detected protein

  • Peptide competition: Pre-incubation with immunizing peptide should abolish specific signal

• Technical validation across methods:

  • Concordance between different techniques (WB, IHC, IF, flow cytometry)

  • Consistent subcellular localization patterns matching known biology

  • Reproducible molecular weight detection (27 kDa for TMUB1)

Published research demonstrates that TMUB1 antibodies like clone EPR14066 show complete signal loss in TMUB1 knockout cell lines by Western blot, providing strong evidence for specificity .

How should researchers analyze TMUB1 expression in relation to PD-L1 and cancer progression?

When analyzing TMUB1 expression in cancer contexts, researchers should employ these analytical approaches:

• Correlation analysis methods:

  • Quantitative assessment of TMUB1 and PD-L1 protein expression in patient samples

  • Statistical correlation with clinical parameters including patient survival

  • Analysis of relationship with CD8+ T cell infiltration in tumor microenvironment

• Mechanistic investigation strategies:

  • Assessment of membrane-localized PD-L1 in relation to TMUB1 expression levels

  • Measurement of PD-L1 post-translational modifications (glycosylation, ubiquitination)

  • Evaluation of TMUB1-PD-L1-HUWE1 interaction dynamics

• Prognostic significance evaluation:

  • Kaplan-Meier survival analysis stratified by TMUB1 expression levels

  • Multivariate analysis to determine independent prognostic value

  • Assessment of TMUB1 as a predictive biomarker for immunotherapy response

Research has demonstrated that TMUB1 protein levels correlate with PD-L1 expression in human tumor tissue, with high expression associated with poor patient survival rates and decreased CD8+ T cell infiltration, suggesting its potential utility as both a prognostic marker and therapeutic target .

What is the mechanism by which TMUB1 regulates PD-L1 and affects tumor immune evasion?

TMUB1 regulates PD-L1 through a sophisticated mechanism affecting post-translational modifications:

• Competitive binding mechanism:

  • TMUB1 competes with HUWE1 (E3 ubiquitin ligase) for interaction with PD-L1

  • This competition occurs in the endoplasmic reticulum

  • By outcompeting HUWE1, TMUB1 inhibits PD-L1 polyubiquitination at K281

• Enhancement of PD-L1 glycosylation:

  • TMUB1 recruits STT3A to PD-L1

  • This recruitment enhances N-glycosylation of PD-L1

  • Increased glycosylation promotes PD-L1 stability and maturation

• Impact on membrane localization:

  • TMUB1 overexpression significantly increases membrane-localized PD-L1

  • Conversely, TMUB1 knockdown decreases membrane-localized PD-L1

  • Membrane-localized PD-L1 directly inhibits anti-tumor immunity by binding to PD-1 on T cells

• Functional consequences:

  • TMUB1 knockdown attenuates tumor cell-induced immune suppression

  • This leads to increased T cell-mediated death of cancer cells

  • TMUB1 downregulation increases IFN-γ and TNF-α production in co-cultured PBMCs

This mechanistic understanding provides a foundation for developing therapeutic strategies targeting the TMUB1-PD-L1 axis to enhance anti-tumor immunity .

How can researchers design peptide-based therapeutics targeting the TMUB1-PD-L1 interaction?

Development of peptide-based therapeutics targeting TMUB1-PD-L1 interaction requires a systematic approach:

• Interface mapping and peptide design:

  • Define the precise binding interface between TMUB1 and PD-L1

  • Design synthetic peptides that mimic critical interaction regions

  • Engineer peptides for optimal binding affinity and specificity

• Peptide optimization strategies:

  • Incorporate cell-penetrating motifs for intracellular delivery

  • Modify amino acids to enhance stability and half-life

  • Test various lengths and conformational constraints to maximize efficacy

• Functional validation methods:

  • Competition binding assays to confirm displacement of TMUB1-PD-L1 interaction

  • Assessment of PD-L1 glycosylation, ubiquitination, and membrane expression

  • T cell activation assays to demonstrate enhanced immune response

• In vivo evaluation approach:

  • Test peptide efficacy in tumor-bearing mice

  • Measure tumor growth inhibition and CD8+ T cell infiltration

  • Assess synergy with established immunotherapy approaches

Research has demonstrated that synthetic peptides engineered to compete with TMUB1 significantly promote antitumor immunity and suppress tumor growth in mice, validating this approach as a promising immunotherapeutic strategy .

What experimental approaches can assess the clinical relevance of TMUB1 in cancer patients?

To establish TMUB1's clinical relevance in cancer, researchers should implement these experimental approaches:

• Patient sample analysis methods:

  • Immunohistochemical assessment of TMUB1 and PD-L1 co-expression

  • Correlation with clinical parameters including tumor stage, grade, and patient outcomes

  • Multi-parameter analysis with immune cell infiltration markers

• Biomarker development strategy:

  • Development of standardized IHC protocols for clinical sample evaluation

  • Establishment of scoring systems for TMUB1 expression

  • Integration with existing biomarker panels for patient stratification

• Translational research approaches:

  • Analysis of TMUB1 expression in pre- and post-treatment biopsies

  • Correlation with response to immunotherapy

  • Prospective studies to validate predictive value

• Data integration methods:

  • Mining cancer genomics databases (e.g., TCGA)

  • Analysis of TMUB1 expression correlation with T cell infiltration signatures

  • Multivariate models incorporating TMUB1 with other prognostic factors

Studies have revealed that TMUB1 protein levels correlate with PD-L1 expression in human tumor tissue, with high expression associated with poor patient survival rates. Additionally, CD8+ T cell infiltration in patients' tumor tissue was negatively correlated with TMUB1 protein levels, suggesting its potential as both a prognostic marker and therapeutic target .

What are emerging areas for TMUB1 research beyond cancer immunotherapy?

While TMUB1's role in PD-L1 regulation has gained significant attention, several other research directions warrant exploration:

• Metabolic regulation roles:

  • Further investigation into TMUB1's involvement in sterol-regulated ubiquitination and degradation of HMG-CoA reductase (HMGCR)

  • Potential implications for cholesterol metabolism and related disorders

  • Connections between metabolic regulation and cancer progression

• Neurobiological functions:

  • Deeper exploration of TMUB1's role in AMPA-selective glutamate receptor GRIA2 recycling

  • Implications for synaptic plasticity and neuronal function

  • Potential relevance to neurological or neurodegenerative conditions

• Liver regeneration and hepatocyte growth:

  • Mechanistic studies of TMUB1 as a negative regulator of hepatocyte growth during regeneration

  • Relevance to liver diseases and regenerative medicine

  • Therapeutic potential in conditions requiring hepatocyte proliferation modulation

• Cell cycle and centrosome regulation:

  • Investigation of TMUB1's contribution to translation during cell-cycle progression

  • Role in centrosome assembly and implications for genomic stability

  • Connections with tumor suppressor CDKN2A and NPM1

These diverse functions suggest TMUB1 may have broader significance across multiple biological systems and disease contexts beyond its established role in cancer immunology .

What technological advances will facilitate the next generation of TMUB1 research?

Emerging technologies will enable more sophisticated investigation of TMUB1 biology:

• Advanced structural biology approaches:

  • Cryo-electron microscopy to resolve TMUB1-protein complexes at high resolution

  • Hydrogen-deuterium exchange mass spectrometry to map dynamic interaction interfaces

  • Computational modeling to predict druggable pockets within the TMUB1-PD-L1 interface

• CRISPR-based methodologies:

  • Base editing for precise modification of TMUB1 at endogenous loci

  • CRISPRi/CRISPRa for temporal control of TMUB1 expression

  • High-throughput CRISPR screens to identify synthetic lethal interactions with TMUB1

• Single-cell and spatial technologies:

  • Single-cell proteomics to map TMUB1 expression heterogeneity

  • Spatial transcriptomics to correlate TMUB1 with immune cell distribution

  • Multiplexed imaging to visualize TMUB1-protein interactions in situ

• Advanced therapeutic modalities:

  • Targeted protein degradation approaches (PROTACs) for TMUB1

  • mRNA therapeutics to modulate TMUB1 expression

  • Nanoparticle-based delivery of TMUB1-targeting agents

These technological advances will enable deeper mechanistic understanding and more precise therapeutic targeting of TMUB1 in various disease contexts.

How might TMUB1-targeted therapies be integrated into existing cancer treatment paradigms?

The integration of TMUB1-targeted therapies into cancer treatment requires consideration of several strategic approaches:

• Combination therapy strategies:

  • Synergistic potential with existing immune checkpoint inhibitors (anti-PD-1/PD-L1)

  • Sequential treatment protocols with conventional therapies (chemotherapy, radiation)

  • Integration with other targeted therapies based on tumor-specific alterations

• Patient selection approaches:

  • Development of companion diagnostics for TMUB1/PD-L1 expression

  • Identification of biomarker signatures predicting response

  • Stratification based on immune infiltration profiles

• Resistance management strategies:

  • Monitoring for adaptive resistance mechanisms

  • Development of second-generation TMUB1 inhibitors

  • Rational design of multi-target approaches

• Clinical trial design considerations:

  • Adaptive trial designs for rapid assessment of efficacy

  • Incorporation of pharmacodynamic endpoints

  • Tissue and liquid biopsy protocols for mechanism confirmation

Research suggests that targeting the TMUB1-PD-L1 axis could enhance the efficacy of existing immunotherapies by promoting antitumor immunity through increased T cell activation and tumor cell killing, representing a promising strategy for overcoming resistance to current immune checkpoint blockade therapies .